Synaptive Medical announced today that it received FDA 510(k) clearance for its near-infrared fluoresence visualization module on its robotic exoscope. The Toronto-based company can now add its Modus IR module to the existing fluorescence offering on the 4K, 3D Modus X system. Modus IR bolsters the capabilities of the exoscope across all neurosurgical procedures, as well as in plastic and ENT surgery.
Related: Implantica prepares for FDA approval of acid reflux device
Synaptive’s newly approved IR mode offers visualization of indocyanine green (ICG) fluorescent dye. ICG causes blood to fluoresce under infrared light and helps with the visualization of vessels and blood flow.
Modus X features a fluorescence feature powered by customized LED lighting. It enables visualization of fluorescent tissue and surrounding anatomy simultaneously, according to a news release. This provides additional anatomical context while performing complex microsurgical techniques.
Combining intraoperative NIR fluorescence visualization with Synaptive’s MRI and tractography-enabled neuro-navigation enhances the system’s perioperative approach to diagnosing and treating cerebrovascular diseases.
Synaptive Medical launched the latest generation of its Modus X system about a year ago.
“The availability of IR fluorescence is a game changer, making Modus X an unrivaled alternative to traditional surgical visualization across neurosurgery and beyond,” said Cameron Piron, chief strategy officer, president and co-founder of Synaptive Medical. “The continued development of this platform over the last decade further demonstrates our commitment to pushing the boundaries to develop the best tools to support our clinicians in delivering the best care they can to their patients.”
